Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Muscadine Grape Extract in Advanced Malignancy
NCT02583269Phase 1Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Mar 2016
- Primary completion
- Dec 2017
- Modality
- Dietary Supplement, PE (Plant Extract)
- Countries
- 1
01
Overview
Phase 1, open-label trial of Muscadine Grape Skin Extract in solid tumor (advanced stage) (5 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Dose-Limiting Toxicity at 29 days. Started Mar 2016; status: completed.
02
Drugs
Muscadine Grape Skin Extract
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02583269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02583269.